Squamous cell carcinoma of the corpus uteri

Squamous cell carcinoma of the corpus uteri is an extremely rare malignant tumor arising from the endometrium (the lining of the uterus or womb) in which the cancer cells are of squamous type rather than the far more common glandular (adenocarcinoma) type. To be classified as a pure squamous cell carcinoma of the endometrium, the tumor must contain no glandular component and must not arise from or be connected to the squamous epithelium of the cervix. This distinction is critical for diagnosis and is established through careful histopathological examination. The disease primarily affects the female reproductive system, specifically the body of the uterus (corpus uteri). Patients typically present with symptoms similar to other endometrial cancers, including abnormal uterine bleeding (particularly postmenopausal bleeding), pelvic pain, and sometimes vaginal discharge. The disease predominantly affects postmenopausal women, often in the sixth to seventh decades of life. Some reported associations include chronic inflammation of the endometrium, pyometra (collection of pus in the uterus), cervical stenosis, and prior radiation therapy, though the exact etiology remains poorly understood. Due to its extreme rarity, there are no standardized treatment guidelines specific to this histological subtype. Management generally follows principles used for other endometrial carcinomas and typically involves total hysterectomy with bilateral salpingo-oophorectomy (surgical removal of the uterus, fallopian tubes, and ovaries), often accompanied by pelvic and para-aortic lymph node dissection for staging purposes. Adjuvant radiation therapy and/or chemotherapy may be considered depending on the stage at diagnosis. The prognosis is generally considered to be poor compared to typical endometrial adenocarcinomas, partly because many cases are diagnosed at an advanced stage. Given the limited number of reported cases in the medical literature, evidence regarding optimal treatment strategies and long-term outcomes remains sparse.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Squamous cell carcinoma of the corpus uteri